Longboard Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

De CEO Longboard Pharmaceuticals is Kevin Lind, benoemd in Mar2020, heeft een ambtstermijn van 4.67 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.05M, bestaande uit 29.7% salaris en 70.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.93% van de aandelen van het bedrijf, ter waarde $ 21.75M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.8 jaar en 3.9 jaar.

Belangrijke informatie

Kevin Lind

Algemeen directeur

US$2.1m

Totale compensatie

Percentage CEO-salaris	29.7%
Dienstverband CEO	4.7yrs
Eigendom CEO	0.9%
Management gemiddelde ambtstermijn	3.8yrs
Gemiddelde ambtstermijn bestuur	3.9yrs

Recente managementupdates

Recent updates

Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management

Oct 15

My Strategy For Longboard Pharmaceuticals After Its Big Run

Aug 28

We Think Longboard Pharmaceuticals (NASDAQ:LBPH) Can Afford To Drive Business Growth

Jul 12

Longboard Pharmaceuticals: After Stellar Gains, A Period Of Relative Calm Seems Likely

Mar 16

Will Longboard Pharmaceuticals (NASDAQ:LBPH) Spend Its Cash Wisely?

Oct 03

We're Keeping An Eye On Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Rate

Dec 25

Companies Like Longboard Pharmaceuticals (NASDAQ:LBPH) Are In A Position To Invest In Growth

Sep 10

We're Hopeful That Longboard Pharmaceuticals (NASDAQ:LBPH) Will Use Its Cash Wisely

May 28

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Good Position To Deliver On Growth Plans

Feb 11

Here's Why We're Not At All Concerned With Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Situation

Oct 27

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Strong Position To Grow Its Business

Jun 12

Longboard Pharmaceuticals EPS beats by $0.29

May 10

Analyse CEO-vergoeding

Hoe is Kevin Lind's beloning veranderd ten opzichte van Longboard Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$76m
Jun 30 2024	n/a	n/a	-US$65m
Mar 31 2024	n/a	n/a	-US$58m
Dec 31 2023	US$2m	US$610k	-US$54m
Sep 30 2023	n/a	n/a	-US$51m
Jun 30 2023	n/a	n/a	-US$49m
Mar 31 2023	n/a	n/a	-US$46m
Dec 31 2022	US$2m	US$572k	-US$44m
Sep 30 2022	n/a	n/a	-US$41m
Jun 30 2022	n/a	n/a	-US$36m
Mar 31 2022	n/a	n/a	-US$32m
Dec 31 2021	US$875k	US$547k	-US$28m
Sep 30 2021	n/a	n/a	-US$29m
Jun 30 2021	n/a	n/a	-US$25m
Mar 31 2021	n/a	n/a	-US$20m
Dec 31 2020	US$2m	US$332k	-US$14m

Compensatie versus markt: De totale vergoeding ($USD 2.05M ) Kevin } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.54M ).

Compensatie versus inkomsten: De vergoeding van Kevin is gestegen terwijl het bedrijf verliesgevend is.

CEO

Kevin Lind (48 yo)

4.7yrs

Tenure

US$2,053,804

Compensatie

Mr. Kevin R. Lind serves as President and Chief Executive Officer at Longboard Pharmaceuticals, Inc. since March 2020 and also serves as its director since January 2020. He serves as Director at Ceek Women...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Kevin Lind	President	4.7yrs	US$2.05m	0.93% $ 21.8m
Brandi Roberts	Executive VP & CFO	3.8yrs	US$1.03m	0% $ 0
Randall Kaye	Executive VP & Chief Medical Officer	2.7yrs	US$1.16m	0.12% $ 2.9m
Chadwick Orevillo	Executive VP & Head of Operations	no data	geen gegevens	geen gegevens
Steven Spector	Executive VP	3.8yrs	geen gegevens	geen gegevens

3.8yrs

Gemiddelde duur

54.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van LBPH wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Kevin Lind	President	4.8yrs	US$2.05m	0.93% $ 21.8m
Phillip Schneider	Independent Director	3.9yrs	US$121.80k	0% $ 0
Casey Lynch	Independent Director	3.8yrs	US$112.80k	0% $ 0
Paul Sekhri	Independent Chairman of the Board	3.9yrs	US$145.81k	0% $ 0
Vincent Aurentz	Independent Director	4.8yrs	US$109.34k	0% $ 0
Corinne Le Goff	Independent Director	3.7yrs	US$114.81k	0% $ 0

3.9yrs

Gemiddelde duur

57.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van LBPH wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).

Longboard Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Longboard Pharmaceuticals, Inc., Annual General Meeting, May 23, 2024

Insufficient new directors

High number of new and inexperienced directors

Longboard Pharmaceuticals, Inc., Annual General Meeting, May 24, 2022

Recent updates

Longboard Pharmaceuticals Initiates Phase 3 DEEp Ocean Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)

Langkawi Corporation entered into an Agreement and Plan of Merger to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.4 billion.

Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

My Strategy For Longboard Pharmaceuticals After Its Big Run

Longboard Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Longboard Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

We Think Longboard Pharmaceuticals (NASDAQ:LBPH) Can Afford To Drive Business Growth

Longboard Pharmaceuticals, Inc.(NasdaqGM:LBPH) dropped from Russell Small Cap Comp Value Index

Longboard Pharmaceuticals, Inc. Receives Breakthrough Therapy Designation for Bexicaserin (LP352)

Longboard Pharmaceuticals, Inc. Announces Positive Interim Results from Its Ongoing 52-Week Open-Label Extension of the Pacific Study Evaluating Bexicaserin (Lp352)

Price target decreased by 7.2% to US$41.75

New major risk - Shareholder dilution

Longboard Pharmaceuticals, Inc., Annual General Meeting, May 23, 2024

Insufficient new directors

Longboard Pharmaceuticals, Inc. announced that it has received $59.85 million in funding from Farallon Capital Management, L.L.C.

Longboard Pharmaceuticals, Inc. announced that it has received $59.85 million in funding from Farallon Capital Management, L.L.C.

Longboard Pharmaceuticals: After Stellar Gains, A Period Of Relative Calm Seems Likely

New major risk - Revenue and earnings growth

Longboard Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New major risk - Shareholder dilution

Longboard Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $210 million.

Price target increased by 43% to US$28.67

Longboard Pharmaceuticals, Inc. Announces Positive Topline Data from the Pacific Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (Dees)

Longboard Pharmaceuticals Announces Initiation of First-In-Human Phase 1 Clinical Study of Lp659 in Adult Healthy Volunteers

New minor risk - Market cap size

New minor risk - Share price stability

Will Longboard Pharmaceuticals (NASDAQ:LBPH) Spend Its Cash Wisely?

Longboard Pharmaceuticals, Inc. Completes Enrollment of Phase 1b/2a Pacific Study Evaluating LP352 for the Treatment of Developmental and Epileptic Encephalopathies

New major risk - Financial position

Price target decreased by 14% to US$17.00

Longboard Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $20 million.

Longboard Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $20 million.

High number of new and inexperienced directors

We're Keeping An Eye On Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Rate

Longboard Pharmaceuticals Announces Positive Topline Data from A Phase 1 Clinical Study Evaluating Central Nervous System Pharmacokinetics and Pharmacodynamics of LP352 in Healthy Volunteers

Companies Like Longboard Pharmaceuticals (NASDAQ:LBPH) Are In A Position To Invest In Growth

We're Hopeful That Longboard Pharmaceuticals (NASDAQ:LBPH) Will Use Its Cash Wisely

Price target decreased to US$19.74

Price target decreased to US$22.80

Longboard Pharmaceuticals, Inc., Annual General Meeting, May 24, 2022

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not At All Concerned With Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Situation

Longboard Pharmaceuticals Successfully Completes LP352 Multiple Ascending Dose Portion of Phase 1 Clinical Trial in Healthy Volunteers, Plans to Initiate Phase 1b/2a Clinical Trial

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Strong Position To Grow Its Business

Longboard Pharmaceuticals Provides Corporate Update

Longboard Pharmaceuticals EPS beats by $0.29

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd